- AIM ImmunoTech amended its equity distribution agreement with Maxim Group to expand its at-the-market stock offering.
- Amendment removes prior $3 million cap on shares that could be sold under the program.
- Shares will be issued from time to time under AIM ImmunoTech’s effective Form S-3 shelf registration statement.
- Prospectus supplement is being updated to increase number of shares eligible for sale in offering.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-016179), on April 10, 2026, and is solely responsible for the information contained therein.
Comments